2024
Phylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
Cudahy P, Liu P, Warren J, Sobkowiak B, Yang C, Ioerger T, Wu C, Lu P, Wang J, Chang H, Huang H, Cohen T, Lin H. Phylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1562-1570. PMID: 39043390, PMCID: PMC11286038, DOI: 10.3201/eid3008.240021.Peer-Reviewed Original ResearchConceptsM. kansasii lung diseaseM. kansasii pulmonary diseasePulmonary diseaseM. kansasii isolatesSputum mycobacterial cultureWhole-genome sequencingEvaluate risk factorsPhylogeographic analysisAge of participantsGenetic relatednessEnvironmental acquisitionLung diseaseMycobacterial cultureOdds ratioRisk factorsM. kansasiiPatientsDiseasePlantsEnvironmental transmissionIsolatesPark plantingsCDCRisk
2023
Predictive power of wastewater for nowcasting infectious disease transmission: A retrospective case study of five sewershed areas in Louisville, Kentucky
Klaassen F, Holm R, Smith T, Cohen T, Bhatnagar A, Menzies N. Predictive power of wastewater for nowcasting infectious disease transmission: A retrospective case study of five sewershed areas in Louisville, Kentucky. Environmental Research 2023, 240: 117395. PMID: 37838198, PMCID: PMC10863376, DOI: 10.1016/j.envres.2023.117395.Peer-Reviewed Original ResearchConceptsDeath dataSurveillance dataSARS-CoV-2 casesClinical surveillance dataLow-resource settingsRetrospective case studyInfectious disease transmissionTrue infectionEpidemiologic dataSerosurvey dataDeath reportsTraditional surveillance dataDisease trendsInfectious diseasesWastewater dataDisease transmissionPredictive performanceDevelopment of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis
Gunasekera K, Marcy O, Muñoz J, Lopez-Varela E, Sekadde M, Franke M, Bonnet M, Ahmed S, Amanullah F, Anwar A, Augusto O, Aurilio R, Banu S, Batool I, Brands A, Cain K, Carratalá-Castro L, Caws M, Click E, Cranmer L, García-Basteiro A, Hesseling A, Huynh J, Kabir S, Lecca L, Mandalakas A, Mavhunga F, Myint A, Myo K, Nampijja D, Nicol M, Orikiriza P, Palmer M, Sant'Anna C, Siddiqui S, Smith J, Song R, Thuong Thuong N, Ung V, van der Zalm M, Verkuijl S, Viney K, Walters E, Warren J, Zar H, Marais B, Graham S, Debray T, Cohen T, Seddon J. Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis. The Lancet Child & Adolescent Health 2023, 7: 336-346. PMID: 36924781, PMCID: PMC10127218, DOI: 10.1016/s2352-4642(23)00004-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAlgorithmsChildHumansRetrospective StudiesTriageTuberculosisTuberculosis, PulmonaryUnited StatesConceptsTreatment decision algorithmsPrimary health care settingsIndividual participant dataHigh tuberculosis incidencePulmonary tuberculosisManagement of tuberculosisHealth care centersComposite reference standardHealth care settingsClinical featuresTuberculosis incidenceClinical evaluationParticipant dataTreatment decisionsChest X-ray featuresPrimary health care centersFuture prospective evaluationTuberculosis-related mortalityEvidence-based algorithmChest X-rayVariable diagnostic performanceMultivariable prediction modelReference standardEvidence-based approachTuberculosis experts
2021
Evaluating the reliability of mobility metrics from aggregated mobile phone data as proxies for SARS-CoV-2 transmission in the USA: a population-based study
Kishore N, Taylor AR, Jacob PE, Vembar N, Cohen T, Buckee CO, Menzies NA. Evaluating the reliability of mobility metrics from aggregated mobile phone data as proxies for SARS-CoV-2 transmission in the USA: a population-based study. The Lancet Digital Health 2021, 4: e27-e36. PMID: 34740555, PMCID: PMC8563007, DOI: 10.1016/s2589-7500(21)00214-4.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 transmissionPopulation-based studyLaboratory-confirmed casesSARS-CoV-2 pandemicSARS-CoV-2Non-pharmaceutical interventionsCOVID-19 transmissionCOVID-19 casesEpidemiological dataReproduction numberEffective reproduction numberHealth StatisticsEquity of accessEpidemic trajectoriesCOVID-19Public healthTransmission indicatorsPopulation levelContact patternsDevelopment of a Treatment-decision Algorithm for Human Immunodeficiency Virus–uninfected Children Evaluated for Pulmonary Tuberculosis
Gunasekera KS, Walters E, van der Zalm MM, Palmer M, Warren JL, Hesseling AC, Cohen T, Seddon JA. Development of a Treatment-decision Algorithm for Human Immunodeficiency Virus–uninfected Children Evaluated for Pulmonary Tuberculosis. Clinical Infectious Diseases 2021, 73: e904-e912. PMID: 33449999, PMCID: PMC8366829, DOI: 10.1093/cid/ciab018.Peer-Reviewed Original ResearchConceptsPulmonary tuberculosisClinical evidenceXpert MTB/RIFBaseline clinical evaluationChest radiographic resultsRapid treatment initiationNational Tuberculosis ProgrammeTreatment decision algorithmsEvidence-based algorithmMTB/RIFDiagnosis of tuberculosisChest radiographicAntituberculosis treatmentProspective cohortRadiographic resultsTreatment initiationTuberculosis casesTuberculosis ProgrammeClinical evaluationCase definitionTreatment decisionsGlobal burdenChildhood mortalityChildren EvaluatedRapid clinical diagnosis
2020
Household studies provide key insights on the transmission of, and susceptibility to, SARS-CoV-2
Pitzer VE, Cohen T. Household studies provide key insights on the transmission of, and susceptibility to, SARS-CoV-2. The Lancet Infectious Diseases 2020, 20: 1103-1104. PMID: 32562602, PMCID: PMC7832097, DOI: 10.1016/s1473-3099(20)30514-4.Peer-Reviewed Original Research
2016
Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling
Heidebrecht CL, Podewils LJ, Pym A, Mthiyane T, Cohen T. Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling. PLOS ONE 2016, 11: e0153143. PMID: 27050561, PMCID: PMC4822784, DOI: 10.1371/journal.pone.0153143.Peer-Reviewed Original ResearchConceptsIncident TB casesTB casesResistant TBDrug-resistant TB casesRifampicin-resistant tuberculosisMultidrug-resistant tuberculosisDrug susceptibility testingRIF-resistant TBLot Quality Assurance SamplingQuality assurance samplingResistant diseaseHigh burdenRIF resistanceKwaZulu-NatalSusceptibility testingHigh-risk areasTuberculosisRiskGreater proportionBurdenTBDiseaseGeographic heterogeneityCasesRifampicin
2013
Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007.
Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Eurosurveillance 2013, 18 PMID: 24128699, DOI: 10.2807/1560-7917.es2013.18.40.20601.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibiotics, AntitubercularAntitubercular AgentsChildChild, PreschoolDrug Resistance, Multiple, BacterialFemaleFluoroquinolonesHumansInfantInfant, NewbornMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPatient ComplianceProspective StudiesRetrospective StudiesSurveys and QuestionnairesTreatment OutcomeTuberculosis, Multidrug-ResistantUnited KingdomYoung AdultConceptsMultidrug-resistant tuberculosisTreatment outcomesRetrospective-prospective cohort studyWorld Health Organization targetMulti-drug resistant tuberculosisMDR-TB patientsMDR-TB treatmentMDR-TB casesFurther drug resistanceTreatment completion ratesSuccessful treatment outcomeUnited Kingdom guidelinesIndividualised regimensCohort studyMonths treatmentResistant tuberculosisTreatment completionInfectious casesDrug resistanceDrug sensitivitySuccessful outcomeOrganization targetBacteriostatic drugsOutcomesTreatmentRisk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova
Jenkins HE, Ciobanu A, Plesca V, Crudu V, Galusca I, Soltan V, Cohen T. Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 373-380. PMID: 23407226, PMCID: PMC3710709, DOI: 10.5588/ijtld.12.0464.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsContinuity of Patient CareFemaleHumansInstitutionalizationLeast-Squares AnalysisLinear ModelsMaleMedication AdherenceMoldovaMultivariate AnalysisPatient DischargePrisonersProportional Hazards ModelsRetrospective StudiesRisk FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeTuberculosisConceptsMultidrug-resistant tuberculosisMDR-TB patientsRisk factorsHighest MDR-TB ratesDrug resistanceGreater lung pathologyMDR-TB ratesAnti-tuberculosis treatmentIndependent risk factorHuman immunodeficiency virusTB drug resistanceContinuity of careRoutine surveillance dataTuberculosis patientsResistant tuberculosisImmunodeficiency virusLung pathologyTreatment adherenceRetrospective analysisHigh riskPatientsSociodemographic factorsCommunity careSurveillance dataStudy period
2012
Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 812-6. PMID: 22507372, PMCID: PMC3786434, DOI: 10.5588/ijtld.11.0637.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsChi-Square DistributionDrug Resistance, BacterialDrug Therapy, CombinationEthambutolFemaleGeorgia (Republic)HumansIsoniazidLogistic ModelsMaleMicrobial Sensitivity TestsMiddle AgedMultivariate AnalysisMycobacterium tuberculosisPredictive Value of TestsPyrazinamideRetrospective StudiesRifampinRisk AssessmentRisk FactorsSputumTime FactorsTreatment OutcomeTuberculosisConceptsPulmonary tuberculosisPrevious treatmentOutcomes of patientsPulmonary TB patientsSubset of patientsRetrospective record reviewForms of tuberculosisFirst-line drugsHigh TB ratesDrug-resistant formsLower ratesLow tuberculosisTB patientsTuberculosis patientsOptimal management strategyTreatment regimenRecord reviewTB ratesTreatment successTreatment outcomesCountry of GeorgiaPatientsIsoniazid resistanceTuberculosisDrug resistanceIdentifying multidrug resistant tuberculosis transmission hotspots using routinely collected data
Manjourides J, Lin HH, Shin S, Jeffery C, Contreras C, Santa Cruz J, Jave O, Yagui M, Asencios L, Pagano M, Cohen T. Identifying multidrug resistant tuberculosis transmission hotspots using routinely collected data. Tuberculosis 2012, 92: 273-279. PMID: 22401962, PMCID: PMC3323731, DOI: 10.1016/j.tube.2012.02.003.Peer-Reviewed Original ResearchConceptsDrug sensitivity testTransmission hotspotsRetreatment casesDrug-resistant tuberculosis epidemicRisk of MDRTime of diagnosisDrug-resistant diseaseTB casesResistant diseaseTuberculosis epidemicHigh riskUntreated casesProgrammatic dataMDRTBRiskMDRHigh levelsTargeted investigationGeographic areasCasesDiseaseDiagnosisSensitivity tests
2010
Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting
LIN H, SHIN S, BLAYA JA, ZHANG Z, CEGIELSKI P, CONTRERAS C, ASENCIOS L, BONILLA C, BAYONA J, PACIOREK CJ, COHEN T. Assessing spatiotemporal patterns of multidrug-resistant and drug-sensitive tuberculosis in a South American setting. Epidemiology And Infection 2010, 139: 1784-1793. PMID: 21205434, PMCID: PMC3153578, DOI: 10.1017/s0950268810002797.Peer-Reviewed Original ResearchConceptsTB casesMDR diseaseMultidrug-resistant tuberculosis (MDR-TB) casesDrug-sensitive tuberculosisDrug-resistant diseaseDrug susceptibility testingMDR-TBMDR casesTuberculosis casesIncident casesSubgroup analysisInfection controlK statisticInfectious durationAppearance of resistanceDistricts of LimaSusceptibility testingDiseasePatientsTBUrban settingsCasesTuberculosisSettingMDRDevelopment of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment
Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Barnashov A, Tonkel TP, Cohen T. Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment. American Journal Of Respiratory And Critical Care Medicine 2010, 182: 426-432. PMID: 20413630, PMCID: PMC2921603, DOI: 10.1164/rccm.200911-1768oc.Peer-Reviewed Original ResearchConceptsMDR-TB treatmentXDR-TBDrug-resistant tuberculosisMultidrug-resistant (MDR) TBMDR-TB treatment programmeExtensively Drug-Resistant TuberculosisMultidrug-resistant tuberculosis treatmentCox proportional hazards modelDevelopment of XDRMDR-TB therapyTB treatment servicesAmplification of resistanceProportional hazards modelThreefold increaseMDR-TBCavitary lesionsConsecutive patientsAppropriate therapyClinical outcomesTreatment adherenceTuberculosis treatmentInjectable antibioticsTimely initiationPrescribed drugsRetrospective analysis